A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Phase 1/2
60
about 11 years
18+
4 sites in MA, MN, NY +1
About this study
Researchers are testing a new vaccine called EO2463 to treat indolent non-Hodgkin lymphoma. The trial will evaluate the safety, tolerability, and effectiveness of EO2463 alone or in combination with other medications like lenalidomide and rituximab.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive EO2463
- 2.Receive rituximab
- 3.Take lenalidomide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
oral (Oral Capsule), infusion
Primary: Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |, Phase 2: Complete Response Rate, Phase 2: Overall Response Rate
Secondary: Evaluation of Overall Survival
Oncology